Platelet volume and total platelet mass are parameters of platelet activity and have become a prognostic factor in coronary heart disease. We have studied the influence of aspirin on platelet count, volume and total platelet mass in vitro and in a randomized double-blind, placebo-controlled study in 20 healthy young male volunteers in vivo. Aspirin had no influence in vitro on either platelet count, volume or mass. Repeated blood sampling during a 7-day treatment with 250 mg aspirin daily showed an increased platelet count (7.3% on day 1, 3.0% on day 2, 6.8% on day 4 and 9.3% on day 7; p < 0.01) and total platelet mass (7.2, 5.0, 8.6 and 11.5% on days 1, 2, 4 and 7, respectively, p < 0.01). Aspirin treatment without repeated blood withdrawal had no effect. These data indicate that aspirin may affect the circulating platelet mass under certain conditions.

Keywords:
Aspirin, Glycocalicin, Platelets, Thrombopoietin
1.
Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.
2.
Karpatkin S: Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood 1978;51:307–316.
3.
Martin JF, Trowbridge EA, Salmon GL, Slater DN: The relationship between megakaryocyte and platelet volume. Thromb Res 1982;28:461–465.
4.
Martin JF, Trowbridge EA, Salmon G, Plumb J: The biological significance of platelet volume: Its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983;32:443–460.
5.
Corash L, Mok Y, Levin J, Baker G: Regulation of platelet heterogeneity: Effects of thrombocytopenia on platelet volume and density. Exp Hematol 1990;18:205–212.
6.
Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR: Platelet size and age determine platelet function independently. Blood 1984;63:1372–1375.
7.
Truman W, Lioyd P, Frojmovic M: Platelet size affects both micro- and macroaggregation: Contributions of platelet number, volume fraction and cell surface. Thromb Haemost 1987;62:733–741.
8.
Martin JF, Bath PMW, Burr ML: Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338:1409–1411.
9.
Terres W, Becker P, Rosenberg A: Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 1994;97:242–249.
10.
Thompson CB: Selective consumption of large platelets during massive bleeding. BMJ 1985;291:95–96.
11.
McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K: Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995;86:3668–3675.
12.
De Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533–538.
13.
Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565–568.
14.
Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568–571.
15.
Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breto-Gorius J, Cosman D, Vainchenker W: cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571–574.
16.
Emmons RVB, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068–4071.
17.
The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascul- ar ischaemic events. Lancet 1990;338:1338– 1339.
18.
The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827–830.
19.
Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287–1294.
20.
Bath PM: The routine measurement of platelet size using sodium citrate alone as the anticoagulant. Thromb Haemost 1993;70:687–690.
21.
Beer JH, Büchi L, Steiner B: Glycocalicin: A new assay – The normal plasma levels and its potential usefulness in selected diseases. Blood 1994;83:691–702.
22.
Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE: Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514–1518.
23.
Ridker PM, Manson JAE, Buring JE, Müller JE, Hennekens CH: Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990;82:897–902.
24.
D’Erasmo E, Aliberti G, Celi FS, Romagnoli E, Vecci E, Mazzuoli GF: Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction. J Intern Med 1990;227:11–14.
25.
Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 1995;86:419–431.
26.
Maalej N, Folts JD: Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Circulation 1996;93:1201–1205.
27.
O’Brian JR: Shear-induced platelet aggregation. Lancet 1990;335:711–713.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.